Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA-2 study of lisaftoclax + acalabrutinib versus immunochemotherapy in untreated CLL/SLL
2024-514084-26-00Phase 3Authorised
- Sponsor
- Ascentage Pharma
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of lisaftoclax and acalabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: IRC-assessed progression-free survival. Planned start Aug 2025; status: authorised.
02
Drugs
lisaftoclaxacalabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-514084-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514084-26-00.